Logo

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Share this

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Shots:

  • The P-III ENVISION study involves assessing of Givosiran vs PBO in patients with acute hepatic porphyria (AHP)
  • ENVISION study results:74% mean reduction of annualized rate of porphyria attacks; 90% median reduction in composite annualized attack rate (AAR); overall safety and tolerability; AEs (89.6% vs 80.4%); attack free (50% vs 16.3%); @3/6mos. 91%/83% in urinary ALA; @6mos. 73% in urinary levels of PBG; 77% in no. of annualized days on hemin; 73% in composite AAR for patients with any AHP   
  • Givosiran is an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) with its expected NDA and MAA submission in mid-2019

Ref: Alnylam | Image: Investor's Business Daily

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions